From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial
N pts (%)
Complete Response
4
(4.6)
Partial Response
26
(29.9)
Stable disease
41
(47.1)
Progressive disease
16
(18.4)